Study of Bet v1 Antibodies Effect on Eye Allergy Symptoms in Adolescents and Adults With Birch Pollen Allergy
Part of paid clinical trials in Andover, Massachusetts.
- Sponsor
- Regeneron Pharmaceuticals
- Study ID
- NCT07309432
- Phase
- PHASE3
- Status
- Recruiting
Conditions
- Allergic Conjunctivitis
Eligibility Criteria
- Sex
- ALL
- Age
- 12 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- REGN5713 — DRUGAdministered per protocol
- REGN5715 — DRUGAdministered per protocol
- Placebo — DRUGAdministered per protocol
Study Details
This study is researching 2 experimental drugs, REGN5713 and REGN5715. The study drugs will be either of these drugs given alone (either REGN5713 or REGN5715) or given together (REGN5713 and REGN5715) to reduce eye allergy signs and symptoms due to birch tree pollen allergy. The aim of the study is to see how safe and effective the study drugs are at lowering eye allergy signs and symptoms compared with placebo. The study will also evaluate whether the combination (REGN5713-5715) has different effectiveness than REGN5713 or REGN5715 alone. The study is looking at several other research questions, including: * What side effects may happen from taking the study drugs * How much of the study drugs is in the blood at different times * Whether the body makes antibodies against the study drugs (which could make the drug less effective or could lead to side effects)
Key Dates
- Start date
- Jan 10, 2026
- Status verified
- Feb 2026
- Primary completion
- Feb 28, 2027
- Completion
- Jun 15, 2027
Study Design
- Enrollment
- 350 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: REGN5713-5715
- Experimental: REGN5713
- Experimental: REGN5715
- Placebo Comparator: Placebo
Primary Outcome Measure
Ocular itch score in participants receiving REGN5713-5715 compared to placebo [ Time Frame: At Day 8 post-Conjunctival Allergen Challenge (CAC) ]
Central Contacts
- Clinical Trials Administrator844-734-6643
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Andover Eye Associates | Andover | Massachusetts | 01810 | - |
Find similar trials in Andover, MA
Related Studies
- Evaluation of TL-925 for the Treatment of Allergic ConjunctivitisPHASE2 · Recruiting · Telios Pharma, Inc. · Memphis, Tennessee
- Evaluation of TL-925 for the Treatment of Seasonal Allergic ConjunctivitisPHASE2 · Recruiting · Telios Pharma, Inc. · Smyrna, Tennessee